DITRA

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:404546OMIM:614204L40.1
Who is this for?
Show terms as
1FDA treatments9Active trials10Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

DITRA stands for Deficiency of Interleukin-36 Receptor Antagonist. It is a rare genetic skin condition that causes repeated, severe flares of generalized pustular psoriasis. In this disease, the body's immune system becomes overactive because it lacks a natural brake called the interleukin-36 receptor antagonist (IL-36Ra). Without this brake, inflammation spirals out of control, leading to widespread painful skin eruptions covered with tiny pus-filled bumps (pustules), along with high fever, extreme fatigue, and a general feeling of being very unwell. During flares, large areas of the skin become red, swollen, and covered with sheets of sterile pustules. The skin can become very tender and may peel off in sheets. These episodes can be life-threatening if not treated promptly, as patients may develop dangerous complications including infections, organ failure, and severe dehydration. Flares can be triggered by infections, stress, pregnancy, or stopping certain medications, though sometimes they occur without a clear trigger. Treatment has improved significantly in recent years. Historically, doctors used broad immunosuppressive drugs like cyclosporine, methotrexate, retinoids (acitretin), and systemic corticosteroids to control flares, though these had significant side effects. A major breakthrough came with spesolimab (Spevigo), an FDA-approved medication that specifically blocks the interleukin-36 pathway. This targeted therapy can rapidly control flares and represents a game-changer for patients with DITRA. Supportive care during flares, including fluid replacement and skin care, remains important.

Also known as:

Key symptoms:

Widespread red, inflamed skinSheets of tiny pus-filled bumps covering large areas of the bodyHigh fever during flaresExtreme tiredness and feeling very unwellSkin peeling off in large sheetsPainful, tender skinChills and shiveringSwollen and painful jointsElevated white blood cell countNail changes or nail lossBurning or stinging sensation on the skinDehydration during severe flaresSwelling of the legs or feetRecurrent episodes that come and go

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
May 2026Generalized Pustular Psoriasis Registry in Costa Rica

Caja Costarricense de Seguro Social

TrialNOT YET RECRUITING
Mar 2026A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — PHASE2

TrialRECRUITING
Jan 2025A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

Bristol-Myers Squibb

TrialACTIVE NOT RECRUITING
Sep 2024Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

Shanghai Huaota Biopharmaceutical Co., Ltd. — PHASE2, PHASE3

TrialRECRUITING
Jun 2024A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. — PHASE1

TrialACTIVE NOT RECRUITING
Mar 2024A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Takeda — PHASE3

TrialACTIVE NOT RECRUITING
Feb 2024A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Janssen Pharmaceutical K.K. — PHASE3

TrialACTIVE NOT RECRUITING
Oct 2023A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Boehringer Ingelheim — PHASE4

TrialACTIVE NOT RECRUITING
Oct 2023Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

Innovaderm Research Inc.

TrialRECRUITING
Sep 2023CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

CorEvitas

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Kineret

anakinra· Swedish Orphan Biovitrum AB (publ)Orphan Drug

treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

Clinical Trials

9 recruitingView all trials with filters →
Phase 32 trials
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Phase 3
Active
PI: Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.) · Sites: Hokkaido; Ichinomiya +10 more · Age: 1299 yrs
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Phase 3
Active
PI: Study Director (Takeda) · Sites: Nagoya, Aichi-ken; Toyoake, Aichi-ken +18 more · Age: 1899 yrs
Phase 41 trial
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
Phase 4
Active
· Sites: Irvine, California; Fargo, North Dakota +33 more · Age: 1899 yrs
Phase 22 trials
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
Phase 2
Active
· Sites: Auburn Hills, Michigan; New York, New York +55 more · Age: 1275 yrs
A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
Phase 2
Actively Recruiting
· Sites: Beijing, Beijing Municipality; Beijing, Beijing Municipality +30 more · Age: 1875 yrs
Phase 11 trial
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
Phase 1
Active
· Sites: Beijing, Beijing Municipality; Guangzhou, Guangdong +5 more · Age: 1875 yrs
Other2 trials
CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
Actively Recruiting
· Sites: Waltham, Massachusetts · Age: 1899 yrs
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
Active
PI: Bristol Myers Squibb (Bristol-Myers Squibb) · Sites: Tokyo; Tokyo · Age: 1899 yrs

Specialists

10 foundView all specialists →
JP
Jianzhong Zhang, PhD
HAMPTON, VA
Specialist
PI on 2 active trials
SZ
Siyan Zhan
Specialist
PI on 1 active trial
CH
Chang-Yu Hsieh
ALHAMBRA, CA
Specialist
4 DITRA publications
ZF
Zhang Furen
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to DITRA.

Search all travel grants →NORD Financial Assistance ↗

Community

Open DITRAForum →

No community posts yet. Be the first to share your experience with DITRA.

Start the conversation →

Latest news about DITRA

Disease timeline:

New recruiting trial: A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis

A new clinical trial is recruiting patients for DITRA

New recruiting trial: Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

A new clinical trial is recruiting patients for DITRA

New recruiting trial: Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

A new clinical trial is recruiting patients for DITRA

New recruiting trial: CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

A new clinical trial is recruiting patients for DITRA

New recruiting trial: Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis

A new clinical trial is recruiting patients for DITRA

New recruiting trial: Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

A new clinical trial is recruiting patients for DITRA

New recruiting trial: A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

A new clinical trial is recruiting patients for DITRA

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Is spesolimab (Spevigo) available and appropriate for my case, and how do I access it?,What should I do at the first sign of a flare — is there a step-by-step emergency plan?,What triggers should I try to avoid, and are there known factors that make flares more likely?,What is the long-term plan to prevent future flares, and what maintenance therapy options exist?,Should my family members be tested for the IL36RN gene mutation?,What are the risks and side effects of the recommended treatments?,How will this condition affect pregnancy planning, and what treatments are safe during pregnancy?

Common questions about DITRA

What is DITRA?

DITRA stands for Deficiency of Interleukin-36 Receptor Antagonist. It is a rare genetic skin condition that causes repeated, severe flares of generalized pustular psoriasis. In this disease, the body's immune system becomes overactive because it lacks a natural brake called the interleukin-36 receptor antagonist (IL-36Ra). Without this brake, inflammation spirals out of control, leading to widespread painful skin eruptions covered with tiny pus-filled bumps (pustules), along with high fever, extreme fatigue, and a general feeling of being very unwell. During flares, large areas of the skin be

How is DITRA inherited?

DITRA follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for DITRA?

Yes — 9 recruiting clinical trials are currently listed for DITRA on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat DITRA?

10 specialists and care centers treating DITRA are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.